Clinical trial
Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II…
NCT00253500 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00253500 |
|---|---|
| Title | Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer |
| Official title | Prediction of Response or Resistance to Dose Intensified Pre-Operative Epirubicin Therapy of Operable Breast Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | pegfilgrastim, epirubicin hydrochloride, conventional surgery |
| Enrollment | 15 |
| Start date | Jun 1, 2002 |
| Primary completion | Sep 1, 2005 |
| Completion | Dec 1, 2010 |
| First posted | Nov 15, 2005 |
| Last update posted | Jul 24, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: